Neuroblastoma directed therapy by a rational prodrug design of etoposide as a substrate for tyrosine hydroxylase

Cancer Letters

Volumn 197, Issue 1-2, 2003, Pages 219-224

  Jikai, J ^a   Shamis, M ^b   Huebener, N ^a   Schroeder, U ^a   Wrasidlo, W ^a   Wenkel, J ^a   Lange, B ^a   Gaedicke, G ^a   Shabat, D ^b   Lode, H N ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Chemotherapy; Etoposide; Neuroblastoma; Prodrug; Tyrosine hydroxylase

Indexed keywords

3,4 DIHYDROXYPHENYLCARBAMATE; DOPA; ETOPOSIDE; PRODRUG; TYROSINE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; BACTERIUM TRANSFORMATION; CANCER CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG SYNTHESIS; ENZYME ACTIVITY; ESCHERICHIA COLI; EXPRESSION VECTOR; GENE SEQUENCE; GENETIC CODE; MOLECULAR CLONING; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TUMOR CELL LINE; WESTERN BLOTTING;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; MURINAE;

EID: 0038105312     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00104-6     Document Type: Conference Paper

References (11)

1. Kelsey J.L., Horn-Ross P.L. Breast cancer: magnitude of the problem and descriptive epidemiology. Epidemiol. Rev. 15:1993;7-16.
2. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer. 1:2001;118-129.
3. Bagshawe K.D. Antibody-directed enzyme prodrug therapy (ADEPT). Adv. Pharmacol. 24:1993;99-121.
4. Senter P.D. Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy. FASEB J. 4:1990;188-193.
5. Martin J., Stribbling S.M., Poon G.K., Begent R.H., Napier M., Sharma S.K., Springer C.J. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial. Cancer Chemother. Pharmacol. 40:1997;189-201.
6. Sharma S.K., Bagshawe K.D., Melton R.G., Begent R.H. Effect of cyclosporine on immunogenicity of a bacterial enzyme carboxypeptidase G2 in ADEPT. Transplant. Proc. 28:1996;3154-3155.
7. Hande K.R. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur. J. Cancer. 34:1998;1514-1521.
8. Lode H.N., Pertl U., Xiang R., Gaedicke G., Reisfeld R.A. Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma. Med. Pediatr. Oncol. 35:2000;641-646.
9. Wang Y.H., Citron B.A., Ribeiro P., Kaufman S. High-level expression of rat PC12 tyrosine hydroxylase cDNA in Escherichia coli: purification and characterization of the cloned enzyme. Proc. Natl. Acad. Sci. USA. 88:1991;8779-8783.
10. Hooper D., Kawamura M., Hoffman B., Kopin I.J., Hunyady B., Mezey E., Eisenhofer G. Tyrosine hydroxylase assay for detection of low levels of enzyme activity in peripheral tissues. J. Chromatogr. B Biomed. Sci. Appl. 694:1997;317-324.
11. Scudiero D.A., Shoemaker R.H., Paull K.D., Monks A., Tierney S., Nofziger T.H., Currens M.J., Seniff D., Boyd M.R. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 48:1988;4827-4833.